1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6AB55D89A8BBF770585256D340000F5CE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/communicating-clinical-trials-to-avoid-the-class-effect-and-build-a-halo-effect-on-other-indications?opendocument
18
19opendocument
2035.173.234.169
21
22
23
24/bestp/domrep.nsf
25DB




Products & Services Clinical Operations Communicating Clinical Trial Results

Communicating Clinical Trials to Avoid the Class Effect and Build a Halo Effect on Other Indications

DB Image

ID: 4432


Features:


Words: 1,756


Published: Pre-2016


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
This 5-page document contains best practices and supporting graphics related to using clinical trial results to avoid the class effect and create a halo effect for other indications a product may have. Companies run the risk of having physicians interpret the results of a landmark clinical study for a specific product to apply to the drug class as a whole. This document includes practices to avoid that class effect. It also includes information about leveraging success shown for a given indication in a clinical trial to boost sales of the product for other indications. This research comes from Best Practices, LLC's consulting services.

Industries Profiled:
Pharmaceutical; Biotech; Health Care


Companies Profiled:
Abbott Laboratories; Sanofi-aventis; AstraZeneca; Bristol-Myers Squibb; Eli Lilly; GlaxoSmithKline; Janssen; Merck; Pharmacia; Novartis; Schering-Plough

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.